Status:
COMPLETED
BAY 77-1931 Long-term Extension From Phase II Study
Lead Sponsor:
Bayer
Conditions:
Hyperphosphatemia
Eligibility:
All Genders
20-75 years
Phase:
PHASE2
Brief Summary
A long-term study of BAY77-1931 (lanthanum carbonate) for hyperphosphatemia in patients undergoing hemodialysis
Eligibility Criteria
Inclusion
- Undergoing hemodialysis 3 times per week for chronic renal failure for the previous 3 consecutive months at least
Exclusion
- Pre-dialysis serum phosphate levels of 10.0mg/dL during the washout period
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
145 Patients enrolled
Trial Details
Trial ID
NCT00769496
Start Date
January 1 2005
End Date
May 1 2008
Last Update
January 23 2013
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Toyohashi, Aichi-ken, Japan, 441-8023
2
Yatomi, Aichi-ken, Japan, 498-0006
3
Chiba, Chiba, Japan, 261-0011
4
Kashiwa, Chiba, Japan, 277-0084